健康研究2024，Vol.44Issue(3)：241-245,5.DOI:10.19890/j.cnki.issn1674-6449.2024.03.001
2016-2020年杭州市耐多药肺结核治疗转归及其影响因素分析
Treatment outcome and related risk factors of 2016-2020 registered multiple drug-resistant tuberculosis patients in Hangzhou
摘要
Abstract
Objective To study the treatment outcome of patients with multidrug-resistant pulmonary tuberculosis(MDR-PTB)in Hangzhou City and to analyze the factors that influence these outcomes.Methods A cluster sampling method was conducted to enroll participants who met the inclusion criteria from the years 2016 to 2020.Sociodemographic and clinical characteristic information was downloaded from the national tuberculosis information system.The Bivariate and multivariable Cox proportional hazards regression analyses were used to identify related risk factors of treatment outcome.Results A total of 306 MDR patents were enrolled,with an average treatment duration of(630.58±191.62)d and a treatment success rate of 81.1%.The treatment success rates for study subjects who started treatment in the years 2016 to 2020 were 79.5%,70.9%,74.2%,88.5%,and 92.7%,respectively.The trend χ2 test showed significant difference(P<0.01).The variables that were ultimately included in the Cox proportional hazards regression model and showed statistical differences were:starting treatment in 2019(HR=1.52,95%CI=1.04～2.22,P=0.0291),starting treatment in 2020(HR=3.45,95%CI=2.35～5.06,P<0.0001),and age<37 years(HR=1.63,95%CI=1.25～2.11,P=0.0003).Conclusions The treatment efficacy of MDR-PTB in Hangzhou City has exhibited a gradual improvement over the years.It is necessary to focus on strengthening the diagnosis,treatment,and supervision management of middle-aged and elderly patients.关键词
耐多药/肺结核/治疗转归/危险因素Key words
multidrug-resistant/pulmonary tuberculosis/treatment outcome/risk factors分类
医药卫生引用本文复制引用
吴亦斐,陈珺芳,谢立,陆敏,程庆林,黄银燕,贾庆军,李清春..2016-2020年杭州市耐多药肺结核治疗转归及其影响因素分析[J].健康研究,2024,44(3):241-245,5.基金项目
浙江省基础公益研究计划项目(LGF21H190002) （LGF21H190002）
浙江省医药卫生科技计划项目(2020KY238,2021KY951) （2020KY238,2021KY951）
杭州市卫生科技计划项目(A20200280,A20220558) （A20200280,A20220558）
杭州市医药卫生科技项目市科技局引导项目(20220919Y060) （20220919Y060）
